Antiretroviral tedavi ile ilişkili yan etkiler: 260 Hıv/aıds olgusunun değerlendirilmesi

Amaç: Antiretroviral tedavinin (ART) kullanıma girmesiyle HIV'e bağlı ölümler azalmış, HIV/AIDS hastalarının yaşam kaliteleri artmıştır. Bununla beraber ART yan etkiler, tedaviye uyum problemleri, ilaç etkileşimleri ve direnç sorunu ile oldukça karmaşıktır. Bu çalışmada, polikliniğimizde takip edilen HIV/AIDS hastalarında ART'ye bağlı gelişen yan etki prevalansını belirlemeyi amaçladık. Gereç ve yöntem: Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji HIV/AIDS Polikliniğinde Ocak 2006 - Aralık 2011 tarihleri arasında takip edilen 260 hasta çalışma kapsamına alındı. Tedavi alan hastalarda gelişen yan etkilerin sıklığı, nedenleri ve sonuçları takip dosyalarının retrospektif incelemesi ile elde edildi. Bulgular: Polikliniğimizden takipli 260 HIV/AIDS hastasının 171'i (%65.7) ART kullanmakta idi. ART altındaki olguların 123’ünde (%72) tedaviye bağlı yan etkiler gözlendi.
En sık görülen yan etkiler nöropsikiyatrik komplikasyonlar (%30.4), ishal (%9.3) ve hiperlipidemi (%16.9) idi. ART'ye bağlı yan etki gelişen tüm hastaların yalnızca 13 'ünün (%7.6) tedavisi değiştirildi. Sonuç: ART ile ilişkili yan etki prevalansı yüksektir ve tedavi uyumunu bozabilmektedir. Bu nedenle ART altındaki HIV/AIDS hastalarında yan etkilerin yakın takibi son derece önemlidir.

Antiretroviral therapy related side effects: Evaluation of 260 Hiv/aids cases

Purpose: Since introduction of antiretroviral therapy (ART), HIV-related mortality has decreased and quality of life in HIV/AIDS patients has improved. ART is quite complicated due to side effects, drug interractions, adherence and drug resistance problems. In this study, we aimed to determine the side effects related to ART among HIV/AIDS patients followed by our outpatient clinic. Materials and methods: HIV/AIDS patients followed by the Infectious Diseases and Clinical Microbiology HIV/ AIDS Outpatient Clinic between January 2006 and December 2011 were included in this study. Medical records were reviewed to determine the prevalence of side effects, causes and results in HIV/AIDS patients on ART. Results: Of the 260 HIV/AIDS patients 171(65.7%) were under ART. Among these, the number of patients with ART related side effects was 123 (72.0%). The most frequent side effects were neuropsychiatric complications (30.4%), diarrhea (9.3%) and hyperlipidemia (16.9%). ART regimen was changed in 13 (7.6%) of the patients had ART related side effects. Conclusion: The prevalence of ART related side effects are common and it may decrease drug adherence. Hence, close monitoring of ART toxicities in HIV/AIDS patients on ART assumes great importance.

___

  • 1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-733
  • 2. Montaner JS, DeMasi R, Hill AM. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count. AIDS 1998;12:23-28
  • 3. Egger M, Hirschel B, Francioli P, et al Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997;315:1194-1199
  • 4. Shah RM, Bulgiba A, Lee CKC, Haniff J, Ali MM. Highly active antiretroviral therapy reduces mortality and morbidity in patients with AIDS in Sungai Buloh Hospital. J Exp Clin Med 2012;4:239-244
  • 5. Carr A, Amin J. Efficacy and tolerability of initial antiretroviral therapy: a systematic review. AIDS 2009;23:343-353.
  • 6. Cicconi P, Cozzi-Lepri A, Castagna A, et al. Insights into reasons for discontinuation according to year of starting first regimen of highly antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Med 2010;11:104-113
  • 7. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008; 22:395-402.
  • 8. Laurent, C, Kouanfack, C, Koulla-Shiro, S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004;364: 29-34.
  • 9. Pádua CA, César CC, Bonolo P.F, Acurcio FA, Guimarães M.D. High incidence of adverse reactions to initial antiretroviral therapy in Brazil. Braz J Med Biol Res 2006; 39: 495-505.
  • 10. Wester CW, Kim S, Bussmann H., et al. Initial response to highly active antiretroviral therapy in HIV- 1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005; 40: 336-343.
  • 11. Forna F, Liechty CA, Solberg P, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007;4:456-462.
  • 12. Wegzyn CM, Fredrick LM, Stubbs RO, Woodward WC, Norton M. Diarrhea associated with Lopinavir/ Ritonavir-based therapy: Results of a meta-analysis of 1469 HIV-1-infected participants. J Int Assoc Physicians AIDS Care (Chic) 2012;11:252-259.
  • 13. Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review Ther Clin Risk Manag 2008; 4:1023-1033.
  • 14. Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials 2005;6:187-196.
  • 15. Lochet P, Peyrière H, Lotthé A, Mauboussin JM, Delmas B, Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 2003;4:62-66.
  • 16. Bongiovanni M, Cicconi P, Landonio S, et al. Predictive factors of lopinavir/ritonavir discontinuation for drug- related toxicity: results from a cohort of 416 multi- experienced HIV infected individuals. Br J Clin Pharmacol 2008;65:396–406.
  • 17. European Medicines Agency. EPARs for Authorised Medicinal Products for Human Use: Sustiva SmPC. http://www.emea.europa.eu/humandocs/Humans/ EPAR/sustiva/sustiva.htm. (13 August 2009, date last accessed)
  • 18. Horberg M, Tang B, Towner W, et al. Impact of tenofovir on renal function in HIV infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 2010;53:62-69.
  • 19. Rachlis A, Clotet B, Baxter J, et al. Safety, tolerability and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B od C co-infected patients in POWER1 and 3. HIV Clin Trials 2007;4:213-220.
  • 20. Saumoy M, Vidal F, Peraire J, et al. Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? AIDS 2004;18:1741-1742.
  • 21. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2001; 356:1423-1430.
  • 22. Núñez M, Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf 2005;28:53-66.
  • 23. Pulido F, Torralba M. NNRTI hepatotoxicity: efavirenz versus nevirapine. J HIV Ther 2002;7:3-16.
  • 24. Bruck S, Witte S, Brust J, et al. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res 2008;13:343-348.
  • 25. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV- infected subjects. J Infect Dis 2005;191:825-829.
  • 26. O’Grady J, Dieterich D, Joshi D, et al. Increasing burden of liver disease in patients with HIV infection. Lancet 2011;377:1198-1209.
  • 27. Mondy K, Tebas P. Emerging bone problems in patients infected with HIV. Clin Infect Dis 2003;36:101-105.
Pamukkale Tıp Dergisi-Cover
  • ISSN: 1309-9833
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 2008
  • Yayıncı: Prof.Dr.Eylem Değirmenci
Sayıdaki Diğer Makaleler

Afyon bölgesinde gebelerde Toksoplazma ve Rubella seroprevelansı

Gülşah AŞIK, Bekir Serdar ÜNLÜ, Halil ER, Özlem YOLDAŞ, Gülengül KÖKEN, Davut ÇUFALI, Mustafa ALTINDİŞ, Mehmet YILMAZER

Tıp fakültesi öğrencilerinde internet bağımlılığı sıklığı ve etkileyen etmenler

AHMET ERGİN, SÜLEYMAN UTKU UZUN, Ali İhsan BOZKURT

Antiretroviral tedavi ile ilişkili yan etkiler: 260 Hıv/aıds olgusunun değerlendirilmesi

HAYAT KUMBASAR KARAOSMANOĞLU, ÖZLEM ALTUNTAŞ AYDIN, Filiz ÖZYİĞİT, E. Rahşan İNCE, Ramazan KORKUSUZ, Özcan NAZLICAN

Kronik subdural hematom cerrahisinin nadir bir komplikasyonu: Subgaleal serebrospinal sıvı kaçağı. Olgu sunumu

Ergün KARAVELİOĞLU, Olcay ESER, Mehmet Gazi BOYACI

Ayak miçetoması ve karakteristik görüntüleme bulguları: olgu sunumu ve literatür değerlendirmesi

Önder TURNA, Mustafa Devran AYBAR, Yeşim KARAGÖZ, Göksel TUZCU, Esma ERBUDAK, Ergün DİNÇ

Koitus sonrası akut abdomen ile başvuran sezaryen skar gebeliği

Hayri AKSÜT, Bülent YILMAZ, Şadiye MAVİ, Ferit SOYLU, Yakup YALÇIN

İki kız kardeşte fibular hemimeli ve literatür değerlendirmesi

Önder TURNA, Mustafa Devran AYBAR, Göksel TUZCU, Yeşim KARAGÖZ

Evaluation of motor nerve excitability by subtreshold stimuli in diabetic polyneuropathy

Göksemin ACAR, Levent Sinan BİR, Eylem DEĞİRMENCİ, Selahattin GÜR

Çocuklarda tekrarlayan hışıltının nadir bir nedeni: Bronkojenik kist

ŞULE GÖKÇE, Feyza KOC, Gamze TALAY, Nergis ASADOVA, Gizem ŞENYAZAR, Metin DELEBE, Murat Cem DAL, Sadık Sadık AKŞİT

Gebelik sırasında Oral Glukoz Tolerans Testi ihtiyacını azaltmak için açlık kan şekeri kullanımı

OSMAN ŞEVKET, SEDA ATEŞ, Gökhan KILIÇ, Taner MOLLA, Fulya ÖZKAL, Ramazan DANSUK, Sefa KELEKÇİ